No new clinical data were released — this is a routine conference presence announcement. Monitor the WMS conference (Sept 29-Oct 3) for any data readouts or abstracts that could move the stock. The FSHD IND timeline (H2 2026) is the next concrete catalyst.
Price Chart
Executive Summary
Satellos announced four poster presentations at the 31st Annual Congress of the World Muscle Society (WMS) in Hiroshima, Japan (Sept 29-Oct 3, 2026), covering its Phase 2 DMD trials (BASECAMP, TRAILHEAD) and an FSHD study rationale. This is a routine scientific conference update with no new clinical data disclosed, providing visibility for the forazapadin program but lacking material catalysts or financial figures.
Key Facts
- Satellos will present four posters at the 31st WMS Congress (Sept 29-Oct 3, 2026) in Hiroshima, Japan.
- Posters cover BASECAMP (Phase 2a dose comparison in ambulatory DMD boys), TRAILHEAD (open-label long-term safety/efficacy in adult DMD), preclinical-to-human translation of regenerative index, and FSHD study rationale.
- Company plans to submit an IND for forazapadin in FSHD in H2 2026 and expects cash runway through 2027.
Financial Impact
No financial figures disclosed in the filing.
Risk Factors
- No new efficacy or safety data disclosed — posters may contain incremental updates only.
- Forward-looking statements about IND submission and cash runway are subject to clinical and financing risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006046 |
| Document: f6k_091426.htm | 0001171843-26-006046 |
| Document: 0001171843-26-006046-index-headers.html | 0001171843-26-006046 |
| Document: 0001171843-26-006046-index.html | 0001171843-26-006046 |
| Document: 0001171843-26-006046.txt | 0001171843-26-006046 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $6.42 | awaiting T+20 | — | $6.88 (+7.17%) |
Oct 21, 2026 6d ago | 6-K | $6.70 | awaiting T+20 | — | $6.88 (+2.69%) |
Oct 5, 2026 22d ago | 6-K | $8.05 | awaiting T+20 | — | $6.88 (−14.53%) |
Sep 30, 2026 27d ago | 6-K | $8.50 | awaiting T+20 | — | $6.88 (−19.06%) |
Sep 30, 2026 27d ago | Press Release | $8.50 | awaiting T+20 | — | $6.88 (−19.06%) |
Sep 24, 2026 4w ago | 6-K | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.88 (−21.01%) |
Sep 24, 2026 4w ago | Press Release | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.88 (−21.01%) |
Sep 15, 2026 6w ago | 6-K | $9.36 $7.04 | ▼ −24.79% | ▼ −27.51% | $6.88 (−26.50%) |
Sep 9, 2026 6w ago | 6-K | $10.02 $7.63 | ▼ −23.85% | ▼ −26.05% | $6.88 (−31.34%) |
Sep 1, 2026 8w ago | 6-K | $9.08 $8.69 | ▼ −4.30% | ▼ −5.48% | $6.88 (−24.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers